Generic Vosevi Availability

Last updated on Dec 12, 2024.

Vosevi is a brand name of sofosbuvir/velpatasvir/voxilaprevir, approved by the FDA in the following formulation(s):

VOSEVI (sofosbuvir; velpatasvir; voxilaprevir - tablet;oral)

Manufacturer: GILEAD SCIENCES INC
Approval date: July 18, 2017
Strength(s): 400MG;100MG;100MG ^[RLD]

Has a generic version of Vosevi been approved?

No. There is currently no therapeutically equivalent version of Vosevi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vosevi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Combination formulation of three antiviral compounds
Patent 10,912,814
Issued: February 9, 2021
Inventor(s): Chal Ben & Nejati Elham & Pakdaman Rowchanak & Stefanidis Dimitrios
Assignee(s): Gilead Pharmasset LLC
Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
Patent expiration dates:
- June 1, 2037
  ✓
  Drug product
Patent 11,116,783
Patent expiration dates:
- January 30, 2034
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug product
- January 30, 2034
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug product
Patent 11116783*PE
Patent expiration dates:
- July 30, 2034
Combination formulation of three antiviral compounds
Patent 11,338,007
Issued: May 24, 2022
Inventor(s): Chal Ben & Nejati Elham & Pakdaman Rowchanak & Stefanidis Dimitrios
Assignee(s): Gilead Sciences, Inc.
Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
Patent expiration dates:
- June 1, 2037
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug product
- June 1, 2037
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug product
Combination formulation of three antiviral compounds
Patent 11338007*PE
Issued: May 24, 2022
Inventor(s): Chal Ben & Nejati Elham & Pakdaman Rowchanak & Stefanidis Dimitrios
Assignee(s): Gilead Sciences, Inc.
Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
Patent expiration dates:
- December 1, 2037
Patent 7,964,580
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Patent 7964580*PED
Patent expiration dates:
- September 26, 2029
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,334,270
Issued: December 18, 2012
Inventor(s): Sofia Michael Joseph & Du Jinfa & Wang Peiyuan & Nagarathnam Dhanapalan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidate prodrugs
Patent 8334270*PED
Issued: December 18, 2012
Inventor(s): Sofia Michael Joseph & Du Jinfa & Wang Peiyuan & Nagarathnam Dhanapalan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- September 21, 2028
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,575,135
Issued: November 5, 2013
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Trejo Martin Teresa Alejandra & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Sciences, Inc.
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Antiviral compounds
Patent 8575135*PED
Issued: November 5, 2013
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Trejo Martin Teresa Alejandra & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Sciences, Inc.
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- May 16, 2033
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,580,765
Issued: November 12, 2013
Inventor(s): Sofia Michael Joseph & Du Jinfa & Wang Peiyuan & Nagarathnam Dhanapalan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidate prodrugs
Patent 8580765*PED
Issued: November 12, 2013
Inventor(s): Sofia Michael Joseph & Du Jinfa & Wang Peiyuan & Nagarathnam Dhanapalan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- September 21, 2028
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 8,618,076
Issued: December 31, 2013
Inventor(s): Ross Bruce S. & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- December 11, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- December 11, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidates
Patent 8618076*PED
Issued: December 31, 2013
Inventor(s): Ross Bruce S. & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- June 11, 2031
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 8,633,309
Issued: January 21, 2014
Inventor(s): Ross Bruce & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidates
Patent 8633309*PED
Issued: January 21, 2014
Inventor(s): Ross Bruce & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- September 26, 2029
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,735,372
Issued: May 27, 2014
Inventor(s): Du Jinfa & Nagarathnam Dhanapalan & Sofia Michael Joseph & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidate prodrugs
Patent 8735372*PED
Issued: May 27, 2014
Inventor(s): Du Jinfa & Nagarathnam Dhanapalan & Sofia Michael Joseph & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- September 21, 2028
  ✓
  Pediatric exclusivity
Compositions and methods for treating hepatitis C virus
Patent 8,889,159
Issued: November 18, 2014
Inventor(s): Cleary Darryl G. & Reynolds Charles J. & Berrey Miriam Michelle & Hindes Robert G. & Symonds William T. & Ray Adrian S. & Mo Hongmei & Hebner Christy M. & Oliyai Reza & Zia Vahid & Stefanidis Dimitrios & Pakdaman Rowchanak & Casteel Melissa Jean
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Compositions and methods for treating hepatitis C virus
Patent 8889159*PED
Issued: November 18, 2014
Inventor(s): Cleary Darryl G. & Reynolds Charles J. & Berrey Miriam Michelle & Hindes Robert G. & Symonds William T. & Ray Adrian S. & Mo Hongmei & Hebner Christy M. & Oliyai Reza & Zia Vahid & Stefanidis Dimitrios & Pakdaman Rowchanak & Casteel Melissa Jean
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
Patent expiration dates:
- September 26, 2029
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,921,341
Issued: December 30, 2014
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Trejo Martin Teresa Alejandra & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Antiviral compounds
Patent 8921341*PED
Issued: December 30, 2014
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Trejo Martin Teresa Alejandra & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- May 16, 2033
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,940,718
Issued: January 27, 2015
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Martin Teresa Alejandra Trejo & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Antiviral compounds
Patent 8940718*PED
Issued: January 27, 2015
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James & Tran Chinh Viet & Martin Teresa Alejandra Trejo & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- May 16, 2033
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,957,046
Issued: February 17, 2015
Inventor(s): Du Jinfa & Nagarathnam Dhanapalan & Sofia Michael Joseph & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
Nucleoside phosphoramidate prodrugs
Patent 9,085,573
Issued: July 21, 2015
Inventor(s): Du Jinfa & Nagarathnam Dhanapalan & Sofia Michael Joseph & Wang Peiyuan
Assignee(s): GILEAD PHARMASSET LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidate prodrugs
Patent 9085573*PED
Issued: July 21, 2015
Inventor(s): Du Jinfa & Nagarathnam Dhanapalan & Sofia Michael Joseph & Wang Peiyuan
Assignee(s): GILEAD PHARMASSET LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:
Patent expiration dates:
- September 21, 2028
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 9,284,342
Issued: March 15, 2016
Inventor(s): Ross Bruce S. & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- September 13, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 13, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidates
Patent 9284342*PED
Issued: March 15, 2016
Inventor(s): Ross Bruce S. & Sofia Michael Joseph & Pamulapati Ganapati Reddy & Rachakonda Suguna & Zhang Hai-Ren & Chun Byoung-Kwon & Wang Peiyuan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- March 13, 2031
  ✓
  Pediatric exclusivity
Inhibitors of hepatitis C virus
Patent 9,296,782
Issued: March 29, 2016
Inventor(s): Bjornson Kyla & Canales Eda & Cottell Jeromy J. & Karki Kapil Kumar & Katana Ashley Anne & Kato Darryl & Kobayashi Tetsuya & Link John O. & Martinez Ruben & Phillips Barton W. & Pyun Hyung-Jung & Sangi Michael & Schrier Adam James & Siegel Dustin & Taylor James G. & Tran Chinh Viet & Tr
Assignee(s): Gilead Sciences, Inc.
Compounds of Formula I are disclosed
Patent expiration dates:
- July 17, 2034
  ✓
  Drug substance
  ✓
  Drug product
Antiviral compounds
Patent 9,868,745
Issued: January 16, 2018
Inventor(s): Bacon Elizabeth M. & Cottell Jeromy J. & Katana Ashley Anne & Kato Darryl & Krygowski Evan S. & Link John O. & Taylor James G. & Tran Chinh Viet & Trejo Martin Teresa Alejandra & Yang Zheng-Yu & Zipfel Sheila
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Drug substance
  ✓
  Drug product

More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)

Patient resources

Vosevi drug information

Professional resources

Related treatment guides

Hepatitis C

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Images

Pill GSI 3 is Vosevi sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg — Vosevi sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg (GSI 3)